Essential Partners LLC Has $197,000 Stock Holdings in United Therapeutics Corporation $UTHR

Essential Partners LLC lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 78.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 333 shares of the biotechnology company’s stock after selling 1,247 shares during the quarter. Essential Partners LLC’s holdings in United Therapeutics were worth $197,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Torren Management LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the fourth quarter worth about $31,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the subject of several analyst reports. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Finally, Royal Bank Of Canada boosted their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $648.33.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,921,276.08. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 502,833 shares of company stock valued at $279,377,162 in the last ninety days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $517.71 on Friday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The business has a 50-day moving average of $543.63 and a two-hundred day moving average of $532.44. The company has a market capitalization of $21.98 billion, a P/E ratio of 19.11, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the firm earned $6.63 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.